Transcatheter pulmonary valve replacement: State of the art.

摘要: Background The number of patients undergoing transcatheter pulmonary valve replacement has been steadily increasing, resulting in many research projects focusing on this patient population. This highlighted the need to summarize currently available data. Methods A review literature was conducted and results summarized. Results At present, two commercially valves approved for include Edwards Sapien Medtronic Melody valve. More data published relating valve; included incidence coronary anatomy prohibiting implantation 5%, an conduit disruption 6%, freedom from stent fracture 60% at 30 months. Short medium term outcomes seem be comparable if not superior surgical replacement, but long-term is still lacking. There may also a cost benefit with when compared replacement. Conclusions Transcatheter here stay. The main challenge treating native right ventricular outflow tract needs addressed device development efforts centered area. © 2015 Wiley Periodicals, Inc.